Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. And here is our regular feature in which we highlight a different person each week. This time around, we note that Mestag Therapeutics hired Matthew Sleeman as chief scientific officer. Previously, he worked at Regeneron Pharmaceuticals, where he was vice president of research, immunology, and inflammation.
But all work and no play can make for a dull chief scientific officer.
So in his spare time, Sleeman enjoys going to art galleries. “I get inspired by great art,” he tells us. “One of my favorites is David Hockney. He’s traveled the world and does a lot of work on the iPad. He’s adopted new media and his paintings are so vibrant and creative.… He’s evolved, he’s not static. The colors are almost reminiscent of impressionist art but in a new modern style.…
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in